(Q35730979)

9 August 2017

1 reference

title

Host factors and failure of interferon-alpha treatment in hepatitis C virus (English)

1 reference

9 August 2017

1 reference

1 reference

Bin Gao

1

1 reference

9 August 2017

Feng Hong

series ordinal

2

1 reference

9 August 2017

Svetlana Radaeva

series ordinal

3

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

9 August 2017

1 reference

9 August 2017

39

1 reference

9 August 2017

880-890

1 reference

9 August 2017

4

1 reference

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

9 August 2017

1 reference

Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS.

21 January 2018

1 reference

Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1

21 January 2018

1 reference

IL-1 beta attenuates IFN-alpha beta-induced antiviral activity and STAT1 activation in the liver: involvement of proteasome-dependent pathway

21 January 2018

1 reference

HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

Consequences of alcohol consumption on host defence

21 January 2018

1 reference

Hepatitis C and hepatocellular carcinoma

21 January 2018

1 reference

7 January 2021

Current therapy for chronic hepatitis C.

1 reference

7 January 2021

Genotype and viral load as prognostic indicators in the treatment of hepatitis C.

1 reference

7 January 2021

Hepatitis C virus resistance to antiviral therapy.

1 reference

7 January 2021

Hepatitis C virus and interferon resistance

1 reference

7 January 2021

Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C.

1 reference

7 January 2021

To interfere and to anti-interfere: the interplay between hepatitis C virus and interferon.

1 reference

7 January 2021

Review article: interferon and hepatitis C--factors predicting therapeutic outcome

1 reference

7 January 2021

The human interferon alpha species and receptors

1 reference

7 January 2021

The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action

1 reference

7 January 2021

Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes

1 reference

7 January 2021

Alpha Interferon Inhibits Hepatitis C Virus Replication in Primary Human Hepatocytes Infected In Vitro

1 reference

7 January 2021

Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C.

1 reference

7 January 2021

Antiviral actions of interferons

1 reference

7 January 2021

Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice.

1 reference

7 January 2021

Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes

1 reference

7 January 2021

Regulation of expression of the rat SOCS-3 gene in hepatocytes by growth hormone, interleukin-6 and glucocorticoids mRNA analysis and promoter characterization

1 reference

7 January 2021

IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3

1 reference

7 January 2021

Tumor necrosis factor alpha attenuates interferon alpha signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy.

1 reference

7 January 2021

Expression of suppressors of cytokine signaling during liver regeneration

1 reference

7 January 2021

The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities

1 reference

7 January 2021

Identification of a nuclear Stat1 protein tyrosine phosphatase

1 reference

7 January 2021

Distinct roles of the NH2- and COOH-terminal domains of the protein inhibitor of activated signal transducer and activator of transcription (STAT) 1 (PIAS1) in cytokine-induced PIAS1-Stat1 interaction

1 reference

7 January 2021

Activation of protein kinase A inhibits interferon induction of the Jak/Stat pathway in U266 cells

1 reference

7 January 2021

Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways

1 reference

7 January 2021

Hepatitis viruses and the MAPK pathway: is this a survival strategy?

1 reference

7 January 2021

IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy

1 reference

7 January 2021

Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C.

1 reference

7 January 2021

Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C

1 reference

7 January 2021

Relationship between the intrahepatic expression of interferon-alpha receptor mRNA and the histological progress of hepatitis C virus-associated chronic liver diseases

1 reference

7 January 2021

Increased monocyte nuclear factor-kappaB activation and tumor necrosis factor production in alcoholic hepatitis

1 reference

7 January 2021

Serum levels of cytokines in chronic liver diseases

1 reference

7 January 2021

Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection

1 reference

7 January 2021

Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C.

1 reference

7 January 2021

High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C.

1 reference

7 January 2021

Recurrence of hepatitis C after liver transplantation is associated with increased systemic IL-10 levels

1 reference

7 January 2021

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

1 reference

7 January 2021

Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders

1 reference

7 January 2021

Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression

1 reference

7 January 2021

Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa

1 reference

7 January 2021

Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection.

1 reference

7 January 2021

Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin.

1 reference

7 January 2021

Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy

1 reference

7 January 2021

IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C.

1 reference

7 January 2021

Interleukin-1 can inhibit interferon-beta synthesis and its antiviral action: comparison with tumor necrosis factor

1 reference

7 January 2021

Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease

1 reference

7 January 2021

Determinants of viral clearance and persistence during acute hepatitis C virus infection

1 reference

7 January 2021

Comparative Analysis of Anti-Hepatitis C Virus Activity and Gene Expression Mediated by Alpha, Beta, and Gamma Interferons

1 reference

7 January 2021

Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs

1 reference

7 January 2021

High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial

1 reference

7 January 2021

Alpha- and gamma-interferon versus alpha-interferon alone in chronic hepatitis B. A randomized controlled study

1 reference

7 January 2021

Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance

1 reference

7 January 2021

Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C

1 reference

7 January 2021

Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C.

1 reference

7 January 2021

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

1 reference

7 January 2021

Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy

1 reference

7 January 2021

The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha

1 reference

7 January 2021

Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response

1 reference

7 January 2021

An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis

1 reference

7 January 2021

Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C

1 reference

7 January 2021

Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.

1 reference

7 January 2021

Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C

1 reference

7 January 2021

HLA class II genotypes associated with chronic hepatitis C virus infection and response to alpha-interferon treatment in Poland

1 reference

7 January 2021

Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection

1 reference

7 January 2021

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group

1 reference

7 January 2021

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin

1 reference

7 January 2021

Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States

1 reference

7 January 2021

1 reference

7 January 2021

Immunosenescence and infectious diseases

1 reference

7 January 2021

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

7 January 2021

Obesity and its nurturing effect on hepatitis C.

1 reference

7 January 2021

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

1 reference

7 January 2021

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

1 reference

7 January 2021

Hepatitis C and alcohol: interactions, outcomes, and implications

1 reference

7 January 2021

Hepatitis C and alcohol

1 reference

7 January 2021

Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers

1 reference

7 January 2021

Expression of interferon alfa signaling components in human alcoholic liver disease

1 reference

7 January 2021

The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C.

1 reference

7 January 2021

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

1 reference

7 January 2021

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

7 January 2021

Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C.

1 reference

7 January 2021

Iron and the response to treatment of hepatitis C

1 reference

7 January 2021

Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations

1 reference

7 January 2021

Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon

1 reference

7 January 2021

Cytokines in viral hepatitis

1 reference

7 January 2021

IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20139

1 reference

9 August 2017

1 reference